Handelsavisen
prelaunch
Companies Healthcare EMD.AX
EM
EMD.AX ASX Biotechnology & Medical Research

Emyria Ltd

A$0,04
Open in Charts → Attach watcher ⌖
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Emyria Ltd is a healthcare diagnostics company that provides diagnostic solutions and services, primarily focused on the development and commercialization of diagnostic tests for infectious diseases and other health conditions.

Business. Emyria Ltd (EMD.AX) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is listed on the Australian Securities Exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning EMD.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to EMD.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Emyria Ltd (EMD.AX) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is listed on the Australian Securities Exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    Emyria's capital structure is characterized by a lack of detailed liquidity metrics, as no balance-sheet inputs are available and there is no going-concern language in the source documents. This absence of data prevents a comprehensive assessment of the company's liquidity position.

    Profitability and return metrics are not available for Emyria, as the valuation snapshot does not provide data on return on invested capital (ROIC), margins, or other key performance indicators. Without these metrics, it is not possible to compare Emyria's performance against industry benchmarks or the median for its sector.

    Segment and geographic exposure data are not disclosed in the available financial information. As a result, it is not possible to assess the company's revenue concentration or geographic diversification. This lack of transparency limits the ability to evaluate the company's exposure to regional economic or regulatory risks.

    Growth trajectory data is also limited. The outlook for the current and next fiscal years does not include numeric deltas or revenue history, making it difficult to assess Emyria's growth potential or performance trends over time.

    Risk factors for Emyria include a lack of liquidity data, which could indicate potential financial instability or operational constraints. The company is currently assessed as having low dilution risk, and no adjustments have been applied to the valuation metrics. However, the absence of detailed financial data limits the ability to fully evaluate the company's risk profile.

    Recent events and filings for Emyria are not detailed in the available data. The lack of disclosed events or transcripts prevents an assessment of recent company developments or management commentary that could impact the company's strategic direction or financial performance.

    Key takeaways
    • Emyria's liquidity position cannot be assessed due to the absence of balance-sheet data and going-concern language.
    • Profitability and return metrics are not available, limiting the ability to evaluate the company's performance against industry benchmarks.
    • Segment and geographic exposure data are not disclosed, making it difficult to assess revenue concentration and regional risk.
    • Growth trajectory and revenue history are not provided, hindering the evaluation of the company's performance trends.
    • The company is assessed as having low dilution risk, but the lack of detailed financial data limits the ability to fully evaluate its risk profile.
    • Recent events and filings are not detailed, preventing an assessment of recent company developments or management commentary.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    A$0,04
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Emyria Ltd Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    128.5Kshares short+9.9% vs prior
    1days to cover
    33.9%short of daily vol
    2.7Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    EMD.AXCanonical
    ASX · AUD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage